With over 100,000 kidney transplant procedures performed annually worldwide, this population is projected to expand in the coming decades [1]. While immunosuppressive regimens effectively mitigate graft rejection risks in kidney transplant recipients (KTRs), they concurrently heighten vulnerability to opportunistic infections. Pulmonary, bloodstream, and urinary tract infections represent the most...

Qin Xingsong et al.
BMC Infectious Diseases 2025; 25(1): 641
Lire la suite

Cell-based therapy such as chimeric antigen receptor (CAR) T-cell therapy has transformed cancer treatment, especially for B-cell malignancies, with seven FDA-approved autologous CAR-T therapies demonstrating high response rates [1, 2]. These therapies have provided significant clinical benefits for patients with relapsed or refractory B-cell lymphoma, acute lymphoblastic leukemia, and multiple myeloma...

Lyu Zibai et al.
Experimental Hematology & Oncology 2025; 14(1): 66
Lire la suite

A Nature Reviews Nephrology editorial published in 2024 highlights the rising global prevalence of kidney disease, surpassing all other chronic diseases currently prioritized by the World Health Organization [1]. Chronic Kidney Disease (CKD) is the final stage of kidney disease, in which the kidneys fail, and renal replacement therapy is needed. Renal replacement therapy options include kidney...

Truhan Tayler E. et al.
BMC Nephrology 2025; 26(1): 225
Lire la suite